Physician profile
Susha Panicker
NPI 1558410787
$6,356.99
in general payments reported to CMS, 2019-2025
20 companies · $2,758 in 2025
The $2,758 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $182 · 2022: $980 · 2023: $164 · 2024: $2,273 · 2025: $2,758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,183 · Education: $11.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,182.51 |
| Education | $11.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $885.79 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $711.71 | 2022-2025 | Invega Sustenna, Spravato |
| Teva Pharmaceuticals USA, INC. | $611.58 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $608.62 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $585.42 | 2021-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $497.62 | 2024-2025 | Qelbree |
| Alkermes, INC. | $424.08 | 2021-2025 | Aristada, Lybalvi |
| Corium, LLC | $390.67 | 2024-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $291.49 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $271.30 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $244.45 | 2024-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $211.89 | 2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $197.63 | 2021-2022 | |
| Lundbeck LLC | $188.99 | 2022-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $84.80 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $59.64 | 2025 | Jornay Pm |
| Almatica Pharma LLC | $38.21 | 2022-2024 | Loreev Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $20.44 | 2022 | |
| Indivior INC. | $17.74 | 2025 | Sublocade |
| Avanir Pharmaceuticals, INC. | $14.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susha Panicker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.